<DOC>
	<DOCNO>NCT02333188</DOCNO>
	<brief_summary>This phase I/II trial study side effect genetic analysis-guided dosing paclitaxel albumin-stabilized nanoparticle formulation , fluorouracil , leucovorin calcium , irinotecan hydrochloride ( FOLFIRABRAX ) treat patient gastrointestinal cancer spread part body usually cure controlled treatment . Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , fluorouracil , leucovorin calcium , irinotecan hydrochloride , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Genetic analysis may help doctor determine dose irinotecan hydrochloride patient tolerate .</brief_summary>
	<brief_title>Genetic Analysis-Guided Dosing FOLFIRABRAX Treating Patients With Advanced Gastrointestinal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine dose-limiting toxicity ( DLT ) rate cycle # 1 three uridine diphosphate ( UDP ) glucuronosyltransferase 1 family , polypeptide A1 ( UGT1A1 ) genotype group ( *1/*1 , *1/*28 , *28/*28 ) use genotype-guided dosing irinotecan ( irinotecan hydrochloride ) part FOLFIRABRAX regimen . SECONDARY OBJECTIVES : I . To determine cumulative dose chemotherapy drug ( nab-paclitaxel [ paclitaxel albumin-stabilized nanoparticle formulation ] , irinotecan , 5-FU [ fluorouracil ] ) administer genotype group . II . To determine response rate ( patient measurable disease ) Response Evaluation Criteria Solid Tumors ( RECIST ) ( version 1.1 ) different disease ( pancreatic cancer , biliary tract cancer , esophageal/gastric cancer , adenocarcinoma unknown primary ) treat study . OUTLINE : Patients receive FOLFIRABRAX comprise paclitaxel albumin-stabilized nanoparticle formulation intravenously ( IV ) 0.5 hour , leucovorin calcium IV 2 hour , irinotecan hydrochloride IV 1.5 hour , fluorouracil IV 46 hour day 1 15 . Courses repeat every 4 week 6 month absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic pancreatic adenocarcinoma , gastric adenocarcinoma , cholangiocarcinoma , gall bladder adenocarcinoma , ampullary carcinoma , adenocarcinoma unclear primary ( gastrointestinal primary suspect ) , primary gastrointestinal malignancy treat physician feel FOLFIRABRAX reasonable therapeutic option Patients history obstructive jaundice due primary tumor must metal biliary stent place Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 Life expectancy &gt; 3 month Absolute neutrophil count ( ANC ) &gt; = 1500/ul Hemoglobin &gt; 9 g/dL Platelets &gt; 100,000/ul Total bilirubin = &lt; 1.25 time upper limit normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 time upper limit normal Alkaline phosphatase = &lt; 2.5 time upper limit normal , unless bone metastasis present absence liver metastasis Creatinine = &lt; 1.5 mg/dL Measurable nonmeasurable disease allow , measurable disease evaluable response rate endpoint Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment Negative serum urine beta human chorionic gonadotropin ( betahCG ) pregnancy test screening patient childbearing potential Signed inform consent Prior chemotherapy radiation therapy cancer Inflammatory bowel disease ( Crohn 's disease , ulcerative colitis ) Diarrhea , grade 1 great National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE , version [ v. ] 4.0 ) ; pancreatic cancer patient clinical evidence pancreatic insufficiency must take pancreatic enzyme replacement Neuropathy , grade 2 great NCICTCAE , v. 4.0 Documented brain metastasis Serious underlie medical psychiatric illness would , opinion treat physician , substantially increase risk complication related treatment Active uncontrolled bleeding Pregnancy breastfeed Major surgery within 4 week Previous concurrent malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient previously treat lifetime recurrence risk le 30 % Patients take substrate , inhibitor inducer cytochrome P450 family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) encourage switch alternative drug whenever possible Patients polymorphism UGT1A1 *1 *28 ( e.g. , *6 ) History interstitial lung disease , idiopathic pulmonary fibrosis , silicosis connective tissue disorder Subjects know human immunodeficiency virus ( HIV ) positive , include combination antiretroviral therapy , ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>